Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Report

Global and Region Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：232
  • REPORT CODE：GMM1021340
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above.

    Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death.

    The report details the trend, potential and market size of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Stroke Prevention in Atrial Fibrillation (SPAF) Treatmentmarket, defines the market attractiveness level of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment industry, describes the types of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market and the development prospects and opportunities of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market in Chapter 13.

    By Player:

    • Bayer

    • Gilead

    • Boehringer Ingelheim

    • Bristol-Myers Squibb

    • Daiichi-Sankyo

    • Pfizer

    • Johnson & Johnson

    By Type:

    • Oral Direct Thrombin Inhibitors

    • Oral Direct Factor Xa Inhibitors

    By End-User:

    • Hospitals

    • Clinics

    • Ambulatory Surgical Centers

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    • 7.2 United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    • 7.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    • 7.4 China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    • 7.5 Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    • 7.6 India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    • 7.7 South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption (2017-2022)

    8 Region and Country-wise Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    • 8.4 China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    • 8.6 India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast (2022-2028)

    9 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Direct Thrombin Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Oral Direct Factor Xa Inhibitors Consumption and Growth Rate (2017-2022)

    • 9.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    10 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Oral Direct Thrombin Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Oral Direct Factor Xa Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    11 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Competitive Analysis

    • 14.1 Bayer

      • 14.1.1 Bayer Company Details

      • 14.1.2 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • 14.2 Gilead

      • 14.2.1 Gilead Company Details

      • 14.2.2 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • 14.3 Boehringer Ingelheim

      • 14.3.1 Boehringer Ingelheim Company Details

      • 14.3.2 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • 14.4 Bristol-Myers Squibb

      • 14.4.1 Bristol-Myers Squibb Company Details

      • 14.4.2 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • 14.5 Daiichi-Sankyo

      • 14.5.1 Daiichi-Sankyo Company Details

      • 14.5.2 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • 14.6 Pfizer

      • 14.6.1 Pfizer Company Details

      • 14.6.2 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • 14.7 Johnson & Johnson

      • 14.7.1 Johnson & Johnson Company Details

      • 14.7.2 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment

    • Figure Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Picture

    • Table Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption by Country (2017-2022)

    • Figure United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Direct Thrombin Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Direct Factor Xa Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Direct Thrombin Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Direct Factor Xa Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • Table Gilead (Foundation Year, Company Profile and etc.)

    • Table Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • Table Daiichi-Sankyo (Foundation Year, Company Profile and etc.)

    • Table Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US